Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
PHASE2CompletedINTERVENTIONAL
Enrollment
61
Participants
Timeline
Start Date
June 30, 2003
Primary Completion Date
July 31, 2010
Study Completion Date
July 31, 2010
Conditions
Primary Peritoneal Cavity CancerRecurrent Ovarian Epithelial Cancer
Interventions
DRUG
irofulven
Given IV
Trial Locations (1)
19103
Gynecologic Oncology Group, Philadelphia
All Listed Sponsors
collaborator
Gynecologic Oncology Group
NETWORK
lead
National Cancer Institute (NCI)
NIH
NCT00053365 - Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer | Biotech Hunter | Biotech Hunter